News Bayer bags FDA green light for stroke drug Sunharbo Bayer gets FDA nod for first-in-class oral Factor XIa inhibitor Sunharbo, a potential blockbuster, for secondary stroke prevention.
News Bayer's Hyrnuo moves first-line for lung cancer in China Bayer's oral HER2 inhibitor Hyrnuo has been approved in China as a frontline therapy for advanced, HER2-mutant non-small cell lung cancer.
News Bayer hits "turning point" in recovery plan, says CEO Bayer's pharma unit has reached a "turning point" in its growth trajectory as sales of new medicines rose 6.4% in Q3, says CEO Bill Anderson.
News Bayer gets first approval for stroke drug asundexian Bayer's oral Factor XIa inhibitor asundexian has been cleared in its first market, China, for secindary stroke prevention.
News ESMO26: Bayer's Nubeqa finds new prostate cancer role Bayer's prostate cancer drug Nubeqa has reduced the risk of the disease spreading or death by 58% in patients at high risk of disease recurrence.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.